{"entity":{"id":"martine-piccart","kind":"person","name":"Martine Piccart","aka":[],"tldr":"Co-founded the Breast International Group and led HERA, the trial that made adjuvant trastuzumab standard.","summary":"Martine Piccart is Scientific Director of Institut Jules Bordet in Brussels and co-founder of the Breast International Group (BIG), and a past president of the European Society for Medical Oncology (ESMO) and of the European CanCer Organisation. Her specialisms are breast cancer, adjuvant trastuzumab and international trial networks. She led HERA, the New England Journal of Medicine trial of one year of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer, which made adjuvant trastuzumab the standard. Her record links her to the HERA, NSABP B-31 and NCCTG N9831 adjuvant trastuzumab trials. Her publications are listed on PubMed.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Martine_Piccart","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Piccart%20M%5BAuthor%5D%20HERA%20trastuzumab"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab"],"companies":["big"],"institutions":["esmo"],"pathways":[],"terms":[],"trials":["hera-b31-n9831"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Scientific Director, Institut Jules Bordet; Co-founder, Breast International Group","institutionId":"big","specialisms":["Breast cancer","Adjuvant trastuzumab","International trial networks"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Piccart%20M%5BAuthor%5D%20HERA%20trastuzumab"}],"papers":[{"title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer (HERA)","journal":"NEJM","year":2005,"doi":"10.1056/NEJMoa052306"},{"title":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2028485","doi":"10.1056/NEJMoa2028485"},{"title":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2105215","doi":"10.1056/NEJMoa2105215"}],"orcid":"0000-0001-9068-8504"},"route":"/people/martine-piccart/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"company":[{"id":"big","kind":"company","name":"Breast International Group (BIG)","route":"/companies/big/"}],"institution":[{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","route":"/institutions/esmo/"},{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/"}],"trial":[{"id":"hera-b31-n9831","kind":"trial","name":"HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)","route":"/trials/hera-b31-n9831/"}],"paper":[{"id":"paper-ascent-nejm-2021","kind":"paper","name":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","route":"/key-papers/paper-ascent-nejm-2021/"},{"id":"paper-olympia-nejm-2021","kind":"paper","name":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","route":"/key-papers/paper-olympia-nejm-2021/"},{"id":"paper-loi-tils-pooled-early-tnbc-jco-2019","kind":"paper","name":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","route":"/key-papers/paper-loi-tils-pooled-early-tnbc-jco-2019/"},{"id":"paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018","kind":"paper","name":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","route":"/key-papers/paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018/"}]}}